Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED Early Phase 1

Fractional Laser Assisted Delivery of Sculptra® for the Treatment of Striae

NCT03858543 · View on ClinicalTrials.gov ↗

Study Summary

This study evaluates the efficacy of treatment of striae distensae using the combined modality of fractional laser and poly-L lactic acid (Sculptra).

Conditions Studied

Interventions

  • DRUG Poly-L Lactic Acid
  • DEVICE Fractional laser treatment

Study Locations (1)

Michigan

  • Henry Ford Health System — Detroit

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2019-07-15
Est. Completion 2021-01-31
Phase Early Phase 1

Sponsor

Henry Ford Health System

171 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03858543

The ClinicalTrials.gov registry entry for NCT03858543 describes a study currently listed as completed. It is categorized as Early Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Henry Ford Health System, which has 171 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Striae Distensae appearing as the primary indexed condition, and to 2 interventions — of which Poly-L Lactic Acid is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT03858543 reports 1 study location spanning 1 distinct geographic area — top geographies include Michigan. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT03858543 about?

NCT03858543 is a clinical study titled "Fractional Laser Assisted Delivery of Sculptra® for the Treatment of Striae". This study evaluates the efficacy of treatment of striae distensae using the combined modality of fractional laser and poly-L lactic acid (Sculptra).

What is the current status of trial NCT03858543?

This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 10 participants. The study started on 2019-07-15. Estimated completion is 2021-01-31.

What conditions does trial NCT03858543 study?

This clinical trial studies the following conditions: Striae Distensae. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT03858543?

The interventions under investigation include: Poly-L Lactic Acid (DRUG), Fractional laser treatment (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT03858543?

This trial is sponsored by Henry Ford Health System, which has 171 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT03858543 being conducted?

This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial